Akebia Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Akebia Therapeutics reported a decrease in net product revenue for the first quarter of 2026, primarily driven by lower Auryxia sales, partially offset by increased Vafseo revenue.
NASDAQ
Akebia Therapeutics reported a return to net income and significant revenue growth for the nine months ended September 30, 2025, driven by the successful U.S. launch of Vafseo, despite the loss of exclusivity for Auryxia.
NASDAQ
Akebia Therapeutics reported a significant financial turnaround, achieving net income and substantial revenue growth driven by the successful U.S. launch of Vafseo, despite Auryxia's loss of exclusivity.
NASDAQ
Akebia Therapeutics achieves profitability in Q1 2025, driven by the launch of Vafseo and increased Auryxia sales, while navigating Auryxia's loss of exclusivity.
NASDAQ
10-Q: Akebia Therapeutics Reports Q3 2024 Results, Navigates Vafseo Launch and Auryxia Exclusivity Loss
Akebia Therapeutics reports a net loss of $20 million for Q3 2024, with product revenue declining, while preparing for the launch of Vafseo and facing Auryxia's loss of exclusivity.
NASDAQ
Akebia Therapeutics reports a net loss of $8.6 million for Q2 2024, with product revenue of $41.2 million, while preparing for the U.S. launch of Vafseo in January 2025.
NASDAQ
Akebia Therapeutics reports a net loss of $18 million for Q1 2024, with product revenue declining slightly, while focusing on the upcoming launch of Vafseo.